The STAMP trial, which was conducted in two hospitals in Malawi and South Africa, aimed to identify whether urine-based screening for TB in HIV-positive patients could improve outcomes. In an article published in the Lancet last week, Ankur Gupta-Wright et al. confirmed that high-risk subgroups could indeed benefit from urine testing and implementation could contribute towards global targets to reduce tuberculosis mortality.

It is worth noting that Professor Steve Lawn was Chief Investigator on the STAMP trial until his death in 2016.

For the full article, please click here

For the comment, please click here

For Ankur Gupta-Wright’s expert opinion piece on the LSHTM website, please click here